Skip to Main content Skip to Navigation
Journal articles

A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study

Mathilde Hunault-Berger 1 Thibaut Leguay 2 Françoise Huguet 3 Stéphane Leprêtre 4 Eric Deconinck 5, 6, 7 Mario Ojeda-Uribe Caroline Bonmati Martine Escoffre-Barbe 8 Pierre Bories 9 Chantal Himberlin Patrice Chevallier 10 Philippe Rousselot Oumedaly Reman 11 Marie-Laure Boulland 12 Séverine Lissandre 13 Pascal Turlure 14 Didier Bouscary 15, 16 Laurence Sanhes 17 Olivier Legrand 18 Marina Lafage-Pochitaloff 19 Marie C. Béné David Liens Yann Godfrin Norbert Ifrah 20, 1 Hervé Dombret 21, 22
1 CRCINA-ÉQUIPE 7 - Innate Immunity and Immunotherapy
CRCINA - Centre de Recherche en Cancérologie et Immunologie Nantes-Angers
2 CHU Bordeaux [Bordeaux]
3 Laboratoire d'Hématologie [Purpan]
4 GPL - Groupe d'étude des proliférations lymphoïdes
5 RIGHT - Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098)
6 Service d'hématologie
7 IBCT (ex IFR133) - Ingénierie et biologie cellulaire et tissulaire
8 Service d'hématologie clinique
9 Service Hématologie
10 CHU Nantes - Centre hospitalier universitaire de Nantes
11 Laboratoire d'Hématologie Biologique [CHU Caen]
12 HITC - Service d'Hématologie, Immunologie et de Thérapie Cellulaire
13 Service d'hématologie [Tours]
14 Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges]
15 Ligue Nationale Contre le Cancer - Paris
16 IC UM3 (UMR 8104 / U1016) - Institut Cochin
17 Hôpital de Perpignan
18 CHU Saint-Antoine [AP-HP]
19 APHM - Assistance Publique - Hôpitaux de Marseille
20 CHU Angers - Centre Hospitalier Universitaire d'Angers
21 Lymphocyte et cancer
22 Hôpital Saint-Louis
Abstract : PURPOSE: The GRASPALL/GRAALL-SA2-2008 Phase II trial evaluated the safety and efficacy of L-asparaginase encapsulated within erythrocytes (GRASPA®) in patients ≥ 55 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. FINDINGS: Thirty patients received escalating doses of GRASPA® on Day 3 and 6 of induction Phases 1 and 2. The primary efficacy endpoint was asparagine depletion \textless 2 µmol/L for at least 7 days. This was reached in 85 and 71% of patients with 100 and 150 IU/kg respectively but not with 50 IU/kg. Grade 3/4 infection, hypertransaminasemia, hyperbilirubinemia and deep vein thrombosis occurred in 77, 20, 7, and 7% of patients, respectively. No allergic reaction or clinical pancreatitis was observed despite 17% of Grade 3/4 lipase elevation. Anti-asparaginase antibodies were detected in 50% of patients and related to a reduction in the duration of asparagine depletion during induction Phase 2 without decrease of encapsulated L-asparaginase activity. Complete remission rate was 70%. With a median follow-up of 42 months, median overall survival was 15.8 and 9.7 months, in the 100 and 150 IU/kg cohorts respectively. CONCLUSIONS: The addition of GRASPA®, especially at the 100 IU/kg dose level, is feasible in elderly patients without excessive toxicity and associated with durable asparagine depletion. (clinicaltrials.gov identifier NCT01523782)
Keywords : Male Gram-Negative Bacterial Infections Gram-Positive Bacterial Infections Humans Aged Anti-Bacterial Agents Antifungal Agents Antineoplastic Combined Chemotherapy Protocols Asparaginase Asparagine Drug Carriers Drug Compounding Erythrocytes Female Middle Aged Mycoses Philadelphia Chromosome Precursor Cell Lymphoblastic Leukemia-Lymphoma Remission Induction Survival Analysis
Document type :
Journal articles
Complete list of metadata
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01237093
Contributor : Laurent Jonchère <>
Submitted on : Wednesday, December 2, 2015 - 4:37:44 PM
Last modification on : Monday, July 19, 2021 - 12:00:02 PM

Links full text

openaccess

Identifiers

Collections

UNIV-RENNES1 | CNRS | UNIV-FCOMTE | UMR645 | UNAM | UNIV-PARIS5 | COMUE-NORMANDIE | INSERM | USPC | UNIV-RENNES | UNIROUEN | UNICAEN | UNIV-PARIS7 | UNIV-TLSE3 | UNIV-PARIS | UP-SANTE | GPMCND | CRCINA-3I | CRCINA | UNIV-NANTES | UNIV-ANGERS | SORBONNE-UNIVERSITE | SU-TI

Citation

Mathilde Hunault-Berger, Thibaut Leguay, Françoise Huguet, Stéphane Leprêtre, Eric Deconinck, et al.. A Phase 2 study of L-asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL-SA2-2008 study. American Journal of Hematology, Wiley, 2015, 90 (9), pp.811--818. ⟨10.1002/ajh.24093⟩. ⟨hal-01237093⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

821